The initial success of the copyright undeniably reshaped the drug landscape, but betting in companies heavily reliant on generic versions presents a uncertain picture. Although early returns were substantial, the expiration of patents and the emergence of cheaper alternatives have weakened sales. Thus, a thorough analysis of current income sources